Center for Science in the Public Interest v. United States Food and Drug Administration
74 F. Supp. 3d 295
D.D.C.2014Background
- Plaintiffs (Center for Science in the Public Interest and Mercury Policy Project) filed a 2011 citizen petition asking FDA to initiate rulemaking requiring point-of-sale and package labeling to disseminate the 2004 FDA/EPA advisory about mercury in fish for pregnant women, women of child-bearing age, and young children (the "Target Group").
- FDA acknowledged the petition, sent a tentative response within 180 days explaining it was still reviewing the science, and thereafter did not issue a final decision for several years while conducting a broader scientific reassessment of fish consumption and methylmercury risks/benefits.
- From 2006–2014 FDA developed a quantitative methodology to assess net effects of fish consumption on fetal neurodevelopment; in June 2014 FDA published a Final Assessment and a Draft Advisory (to replace the 2004 Advisory) and solicited public comment.
- Plaintiffs sued in March 2014 under the Administrative Procedure Act alleging unreasonable delay and sought a court order compelling FDA to act on the petition; parties cross-moved for summary judgment.
- The core factual/legal tension: methylmercury poses developmental risks, but fish provide neurodevelopmental benefits; FDA contends final substance of any labeling should await completion of its updated scientific and policy work.
- The district court found FDA was actively engaged in the related regulatory process, that waiting for the Draft Advisory to be finalized was a reasonable explanation for delay, and declined to compel action at this time.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether FDA's multi-year failure to issue a final response to the citizen petition is an unreasonable delay under the APA | FDA's delay (years) is unreasonable given agency regulation requires a tentative response in 180 days and the public-health stakes; FDA should be compelled to act | FDA has been engaged in complex, agency-led scientific reassessment; the APA requires action within a "reasonable time" and that depends on complexity; agency waited to finalize labeling decisions until Draft Advisory is complete | Court held FDA's delay was not so egregious as to warrant mandamus or compulsion now; denial of plaintiff's summary judgment and grant of defendant's summary judgment |
| Whether FDA's previous denial of a different petition (CBD petition) shows it could have acted here | FDA's prior prompt denial of a similar petition shows it had capacity and could have decided plaintiffs' petition sooner | The two petitions differed materially; CBD petition was narrower and raised different scientific and legal issues, so its denial does not evidence unreasonable delay here | Court held the prior denial did not demonstrably show inconsistent or unreasonable treatment |
| Whether the public-health stakes (risk to fetuses/children) require expedited judicial relief | High risk to vulnerable populations justifies court compulsion because delay prejudices health | Although health is implicated, FDA's entire docket concerns health and the scientific balance between mercury risk and fish benefits makes this case distinguishable from cases of clear imminent harm | Court concluded the uncertain risk-benefit balance and ongoing agency work weigh against immediate judicial intervention |
| Whether compelling action would unduly interfere with FDA's prioritization of competing agency projects | Plaintiffs: FDA can prioritize mercury labeling now; action would not impair other priorities | FDA: forcing a decision now would divert scarce resources and preclude considered rulemaking tied to the imminent Draft Advisory | Court deferred to FDA's resource allocation and need for deliberation; fourth TRAC factor favors defendant |
Key Cases Cited
- Telecommunications Research & Action Ctr. v. FCC, 750 F.2d 70 (D.C. Cir. 1984) (establishes multi-factor test for reviewing agency delay)
- Pub. Citizen Health Research Group v. Comm’r, Food & Drug Admin., 740 F.2d 21 (D.C. Cir. 1984) (courts may compel agency action when delay threatens public health)
- Mashpee Wampanoag Tribal Council, Inc. v. Norton, 336 F.3d 1094 (D.C. Cir. 2003) (reasonableness of delay depends on complexity and agency resources)
- Sierra Club v. Thomas, 828 F.2d 783 (D.C. Cir. 1987) (courts defer to agencies on complex scientific and technical timetables)
- In re Barr Laboratories, Inc., 930 F.2d 72 (D.C. Cir. 1991) (refusal to compel where mandamus would disrupt agency prioritization)
- Muwekma Tribe v. Babbitt, 133 F. Supp. 2d 30 (D.D.C. 2000) (example of unreasonable delay where agency gave noncommittal estimates and did not deploy resources to mitigate delay)